Close Menu

NEW YORK (GenomeWeb) – IncellDx today announced it received CE marking for it flow cytometry-based test for human papillomavirus.

The company also announced the launch of the test, which combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay. It quantifies the E6/E7 mRNA overexpression by RNA in situ hybridization and combines it with cell cycle DNA, which quantifies proliferation, which IncellDx said is a hallmark of transformation to cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.